The Pentagon wants to test soldiers' testosterone. The label for treating it is narrow.

The Pentagon plans to test U.S. soldiers' testosterone levels to "optimize" their performance, according to Scientific American, and some in the Trump administration describe low testosterone among teenagers as an "existential problem" ^[1][2]. Those are institutional commitments resting on a clinical literature that the physicians quoted in the same report describe as largely silent on healthy men.

Start with what the drug is licensed to do. The U.S. Food and Drug Administration approves testosterone replacement therapy for men with low testosterone "in conjunction with an associated medical condition" ^[8]. That condition list is specific: testicular cancer, hypothalamic disease and pituitary disease, according to Peter Snyder, a professor of medicine at the University of Pennsylvania ^[11]. Michael Irwig, an associate professor of medicine at Harvard Medical School, adds testicular damage from chemotherapy or surgery, HIV/AIDS, mumps infection and obesity ^[12]. For men who actually meet a deficiency diagnosis, the therapy works, and Snyder lists the symptoms it can treat: reduced energy, lower sexual interest, reduced muscle mass and bone density, and lower red blood cell production ^[9][13].

Outside that box, the picture changes. "There's this narrative that, if you have higher testosterone levels, you're healthier, and you're going to live longer," Irwig told Scientific American. "But there actually isn't any evidence showing that" ^[7]. The therapy is not consequence-free either: reported risks include declining fertility, smaller testicles and acne ^[10].

The best-known trial evidence is also narrower than the conversation around it. Men's blood testosterone falls with age, which is what motivated Snyder and colleagues to run the TTrials in the early 2000s: roughly 800 men with lower-than-normal testosterone, randomised to therapy or placebo for a year ^[14][15]. Note the enrolment criterion. Every participant already had below-normal levels, so the trial cannot tell you what supplementation does to a man whose numbers are normal ^[17]. Snyder says the results were "pretty clear," and the excerpt of the article supplied to us breaks off mid-sentence as he begins to describe them, so we are not characterising the findings here ^[15][16].

The demand side is not waiting for the evidence. In July results from a Men's Health poll, about 70 percent of men said their testosterone levels mattered to them, and almost half treated those levels as a measure of "masculinity" ^[4]. Social media promotes "T maxxing" for jawlines, muscle and energy ^[6], and a growing number of cisgender men are buying boosters and synthetic testosterone delivered by injection, gel or patch ^[5]. The same government weighing testosterone optimisation for soldiers is simultaneously working to limit transgender people's access to hormone therapy ^[1][3].

What to watch: the threshold. Any military screening programme has to define "low," and that number determines how many soldiers get flagged for a hormone whose approved indication requires an accompanying diagnosis ^[1][8]. Watch also whether screening is paired with prescribing authority, because a test result with no labelled treatment behind it is an administrative liability rather than a performance gain ^[8]. And watch the fertility side effects, which land differently on a young enlisted population than on the older men the trials studied ^[10][15].